On Dec. 12, 2017, Denali Therapeutics (DNLI) announced the closing of its initial public offering of 15,972,221 shares of its common stock at a price to the public of $18.00 per share. On January 5, 2018, less than one month since it closed the public offering, Denali and Takeda (TSE:4502) announced entering into a strategic option and collaboration agreement to develop and commercialize up to three specified therapeutic product candidates for neurodegenerative diseases.
Expressing his enthusiasm about partnering with Denali, Emiliangelo Ratti, Head of the Neuroscience Therapy Area . . .
This content is for paid subscribers.
Today’s Highlights January 5, 2018